Skip to main content

Keenova Therapeutics plc

MNKTQDelisted
Industry
Pharmaceutical Preparations
SEC CIK
0001567892

Keenova Therapeutics plc was delisted in 2023; its insiders filed their last Form 4 on Jul 23, 2026; 36 institutions reported holding it in 13F filings for Q2 2023, worth $12.4M in total; no superinvestor held it.

Key figures

Insider buys
0
Open market, last 90 days
Insider sells
0
Open market, last 90 days
13F holders
36
Q2 2023, −9 vs. previous quarter
13F value
$12.4M
Reported value at the end of Q2 2023
Superinvestors holding
0
At the end of Q2 2023

Superinvestors holding MNKTQ, Q2 2023

Go to the superinvestors tab

No superinvestor reported holding MNKTQ at the end of Q2 2023.

Latest insider trades

Open-market purchases and sales by Keenova Therapeutics plc insiders from Form 4, newest first.

See all insider trades
Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
May 21, 2026 (view filing)8:59 PM ETMay 19-202 daysMule Edward A and 2 others10% OwnerPPurchase+397.5K$90.50+$36.0M+7.1%6.04M after2 lots
Apr 17, 2026 (view filing)5:23 PM ETApr 15-172 daysMule Edward A and 2 others10% OwnerPPurchase+685.0K$89.70+$61.4M+13.8%5.64M after2 lots
Jan 9, 2026 (view filing)5:26 PM ETJan 72 daysMule Edward A and 2 others10% OwnerPPurchase+250.0K$92.25+$23.1M+5.3%4.95M after
Dec 10, 2025 (view filing)6:14 PM ETDec 82 daysMule Edward A and 2 others10% OwnerPPurchase+131.0K$88.75+$11.6M+2.9%4.70M after
Nov 19, 2025 (view filing)6:39 PM ETNov 17-192 daysMule Edward A and 2 others10% OwnerPPurchase+68.0K$88.88+$6.04M+1.5%4.57M after2 lots
Nov 12, 2025 (view filing)8:16 PM ETNov 102 daysMule Edward A and 2 others10% OwnerPPurchase+290.0K$93.75+$27.2M+6.9%4.50M after
Aug 6, 2025 (view filing)7:45 PM ETAug 4-62 daysGoldentree Asset Management LP and 2 others10% OwnerPPurchase+36.7K$88.21+$3.24M+0.5%7.95M after2 lots
Aug 4, 2025 (view filing)4:45 PM ETAug 13 daysGoldentree Asset Management LP and 2 others10% OwnerPPurchase+50.0K$86.50+$4.33M+0.6%7.91M after
Jul 10, 2024 (view filing)4:30 PM ETJul 82 daysGoldentree Asset Management LP and 2 others10% OwnerPPurchase+13.3K$54.50+$724.9K+0.4%3.33M after
Jun 18, 2024 (view filing)4:30 PM ETJun 144 daysGoldentree Asset Management LP and 2 others10% OwnerPPurchase+275.0K$52.75+$14.5M+9.0%3.31M after

Top 10 13F holders, Q2 2023

The largest institutional positions in Keenova Therapeutics plc at the end of Q2 2023; share changes are against Q1 2023.

See all 36 holders
Institutions holding MNKTQ in Q2 2023
InstitutionSharesValue% of portfolioChange in sharesAction
Bracebridge Capital, LLC2,033,257$2.40M1.91%00.0%Unchanged
Alta Fundamental Advisers LLC1,947,093$2.30M1.26%+1,215,000+166.0%Added
JPMorgan Chase & Co1,316,260$1.55M0.00%−365,378−21.7%Reduced
Hudson Bay Capital Management LP1,041,560$1.23M0.01%−100,000−8.8%Reduced
Continental General Insurance Co880,822$1.04M0.37%+781,154+783.8%Added
Sculptor Capital LP694,649$819.7K0.02%00.0%Unchanged
Vanguard Group Inc644,153$760.1K0.00%00.0%Unchanged
Two Seas Capital LP585,602$691.0K0.15%+568,346+3,293.6%Added
BlackRock Inc.203,658$240.3K0.00%+11,351+5.9%Added
Bank of America Corp156,282$184.4K0.00%−600.0%Reduced